Skip to main content

Table 3 Proteins and peptides showing significant differences

From: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Cohort Change Protein (significant peptidesa/peptides measured)
Pilot study ↑AD vs control AP2B1 (3/3)b, CTSB (2/3), GM2A (2/2), LAMP2 (2/4), and ubiquitin (2/2)
Clinical study I ↓PD vs prodromal AD AP2B1 (1/3)b, CTSF (1/4), LAMP1 (1/3), LAMP2 (3/4), and ubiquitin (2/2)
Clinical study II ↓PD vs control AP2B1 (2/2)b, CTSF (2/4), and ubiquitin (1/2)
↓PD vs AD AP2B1 (2/2)b, C9 (1/5), CTSB (1/3), CTSF (4/4), GM2A (2/2), TCN2 (2/3), and ubiquitin (2/2)
  1. aP value of ≤ 0.05 using Wilcoxon 2-sample rank sum test or Kruskal-Wallis test with Dunn post hoc
  2. bThree peptides were measured in a subset of subjects in the pilot study and all subjects in clinical study I. Two peptides were measured in the rest of the pilot study subjects and clinical study II